Seattle Genetics has emerged as one of the most successful biotechnology companies across the world and this can be attributed to their emphasis on research and innovation when making their products. They offer several drug pipelines and are growing their network to offer drugs in other areas apart from cancer. Through this resolve, they have partnered with leading pharmaceutical manufacturers like GlaxoSmithKline.
Since establishment in 1998, Seattle Genetics has run on the need to come up with solutions that are relevant to the needs that emerge with changes in time. Their antibody-drug conjugate (ADC) technology has been successful and they now have variations of the product for different treatment options.
Such include the SGN-CD33A, mostly used for treating acute myeloid leukemia. SGN-CD19A on the other hand is used in the treatment of non-Hodgkin lymphoma. Their ADCETRIS therapy has been adopted by more than 15,000 lymphoma patients and is currently used in more than 65 countries across the world. Additionally, the U.S. Food and Drug Administration approved the product for distribution.
The co-founder of Seattle Genetics, Clay Seagall has also contributed largely in the development of the company to its current position. He is responsible for various technological innovations and partnerships that have led to the development of superior products. In 2013, Siegall was promoted by Mirna Therapeutics to join their Board of Directors. Mirna Therapeutics specializes in the production of microRNA therapeutics and Dr. Clay Siegall guides them in the production of different products.
Clay B. Siegall, Ph.D.
Clay Siegall, a clinical scientist by profession, is among investors who founded Seattle Genetics in 1998. He works as the CEO of the company and the chair of the Board for more than one decade. His foundation on science and clinical medicine inspired him to lead Seattle Genetics and transform it into an innovation and research institution that is focused on developing unique products that can be applied in cancer treatment.
Under the leadership of Clay Siegall, Seattle Genetics has signed several partnerships including GlaxoSmithKline, AbbVie and Pfizer. Siegall has authored over 70 publications and has 15 patents. He earned his Ph.D. in Genetics from the University of Washington.